An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
- Study Title
- An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy
- Teva Identifier
- TV56286-NDG-20041
- ClinicalTrials.gov Identifier
- NCT07197866
- Study Status
- Recruiting
- Trial Condition(s)
- Multiple System Atrophy
- Interventions
- Drug: TEV-56286
- Study Description
- The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks
Key Participation Requirements
- Gender
- All
- Age group
- Adult, Older Adult
- Age Range
- 30 years and older
- Trial Duration
- September 30, 2025 - May 17, 2029
- Phase
- Phase 2
